Silexion Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2013	FY 2012
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '13 Dec 31, 2013	Dec '12 Dec 31, 2012
Selling, General & Admin	4.49	6.76	0.97	0.24	0.17
Research & Development	4.64	5.82	3.71	1.12	0.79
Operating Expenses	9.13	12.57	4.68	1.36	0.95
Operating Income	-9.13	-12.57	-4.68	-1.36	-0.95
Interest Expense	-0.03	-0.03	-	-0	-0
Interest & Investment Income	0.08	0.03	0.15	0	0.01
Currency Exchange Gain (Loss)	-0.14	-0.25	-0.45	0	0.01
Other Non Operating Income (Expenses)	-0.03	-3.69	-0.1	-	-
Pretax Income	-9.24	-16.51	-5.08	-1.36	-0.94
Income Tax Expense	0	0.01	0.03	-	-
Earnings From Continuing Operations	-9.25	-16.52	-5.11	-1.36	-0.94
Minority Interest in Earnings	-	0.08	0.17	-	-
Net Income	-9.25	-16.44	-4.94	-1.36	-0.94
Net Income to Common	-9.25	-16.44	-4.94	-1.36	-0.94
Shares Outstanding (Basic)	1	0	-	-	-
Shares Outstanding (Diluted)	1	0	-	-	-
EPS (Basic)	-16.23	-395.36	-	-	-
EPS (Diluted)	-16.23	-395.36	-	-	-
Free Cash Flow	-10.74	-8.42	-4.54	-0.8	-0.91
Free Cash Flow Per Share	-18.84	-202.40	-	-	-
EBITDA	-9.13	-12.55	-4.64	-1.36	-0.95
D&A For EBITDA	-0	0.03	0.05	0	0
EBIT	-9.13	-12.57	-4.68	-1.36	-0.95

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q